Literature DB >> 10891977

Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial.

M Vorgerd1, T Grehl, M Jager, K Muller, G Freitag, T Patzold, N Bruns, K Fabian, M Tegenthoff, W Mortier, A Luttmann, J Zange, J P Malin.   

Abstract

OBJECTIVE: To determine whether treatment with creatine can improve exercise intolerance in myophosphorylase deficiency (McArdle disease).
DESIGN: Double-blind, placebo-controlled crossover study with oral creatine monohydrate supplementation. PATIENTS: Nine patients with biochemically and genetically proven McArdle disease were treated. INTERVENTION: Five days of daily high-dose creatine intake (150 mg/kg body weight) were followed by daily low-dose creatine intake (60 mg/kg). Each treatment phase with creatine or placebo lasted 5 weeks. MAIN OUTCOME MEASURES: The effect of treatment was estimated at the end of each treatment phase by recording clinical scores, ergometer exercise test results, phosphorus 31 nuclear magnetic resonance spectroscopy, and surface electromyography.
RESULTS: Of 9 patients, 5 reported improvement of muscle complaints with creatine. Force-time integrals (P =.03) and depletion of phosphocreatine (P =.04) increased significantly during ischemic exercise with creatine. Phosphocreatine depletion also increased significantly during aerobic exercise (P =.006). The decrease of median frequency in surface electromyograms during contraction was significantly larger (P =.03) with creatine.
CONCLUSION: This is the first controlled study indicating that creatine supplementation improves skeletal muscle function in McArdle disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891977     DOI: 10.1001/archneur.57.7.956

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  32 in total

Review 1.  Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V).

Authors:  Rosaline Quinlivan; Andrea Martinuzzi; Benedikt Schoser
Journal:  Cochrane Database Syst Rev       Date:  2014-11-12

Review 2.  Myopathies Related to Glycogen Metabolism Disorders.

Authors:  Mark A Tarnopolsky
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 3.  Molecular genetics of McArdle's disease.

Authors:  G Nogales-Gadea; J Arenas; A L Andreu
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

Review 4.  Treatment of glycogenosys type V (McArdle disease) with creatine and ketogenic diet with clinical scores and with 31P-MRS on working leg muscle.

Authors:  M Vorgerd; J Zange
Journal:  Acta Myol       Date:  2007-07

Review 5.  Pharmacological and nutritional treatment trials in McArdle disease.

Authors:  R M Quinlivan; R J Beynon
Journal:  Acta Myol       Date:  2007-07

6.  Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress.

Authors:  Roberta R Alfieri; Mara A Bonelli; Andrea Cavazzoni; Maurizio Brigotti; Claudia Fumarola; Piero Sestili; Paola Mozzoni; Giuseppe De Palma; Antonio Mutti; Domenica Carnicelli; Federica Vacondio; Claudia Silva; Angelo F Borghetti; Kenneth P Wheeler; Pier Giorgio Petronini
Journal:  J Physiol       Date:  2006-07-27       Impact factor: 5.182

Review 7.  McArdle disease: a unique study model in sports medicine.

Authors:  Alfredo Santalla; Gisela Nogales-Gadea; Niels Ørtenblad; Astrid Brull; Noemi de Luna; Tomàs Pinós; Alejandro Lucia
Journal:  Sports Med       Date:  2014-11       Impact factor: 11.136

8.  The pathogenomics of McArdle disease--genes, enzymes, models, and therapeutic implications.

Authors:  Gisela Nogales-Gadea; Alfredo Santalla; Astrid Brull; Noemi de Luna; Alejandro Lucia; Tomàs Pinós
Journal:  J Inherit Metab Dis       Date:  2014-07-23       Impact factor: 4.982

9.  Oral creatine supplementation facilitates the rehabilitation of disuse atrophy and alters the expression of muscle myogenic factors in humans.

Authors:  P Hespel; B Op't Eijnde; M Van Leemputte; B Ursø; P L Greenhaff; V Labarque; S Dymarkowski; P Van Hecke; E A Richter
Journal:  J Physiol       Date:  2001-10-15       Impact factor: 5.182

Review 10.  Inborn errors of energy metabolism associated with myopathies.

Authors:  Anibh M Das; Ulrike Steuerwald; Sabine Illsinger
Journal:  J Biomed Biotechnol       Date:  2010-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.